摘要
目的:探究用布地奈德福莫特罗粉吸入剂治疗肺结节病的疗效。方法:将40例肺结节病患者作为研究对象。按随机数表法将其分为环磷酰胺组(n=20)和布地奈德福莫特罗组(n=20)。为环磷酰胺组患者采用环磷酰胺进行治疗,为布地奈德福莫特罗组患者采用布地奈德福莫特罗粉吸入剂进行治疗,然后比较两组患者的治疗效果。结果:治疗后,布地奈德福莫特罗组患者中临床疗效为显效的患者有14例(占70.00%),为好转的患者有3例(占15.00%),为无效的患者有3例(占15.00%);环磷酰胺组患者中临床疗效为显效的患者有12例(占60.00%),为好转的患者有3例(占15.00%),为无效的患者有5例(占25.00%)。布地奈德福莫特罗组患者治疗的总有效率〔85.00%(17/20)〕高于环磷酰胺组患者治疗的总有效率〔75.00%(15/20)〕,差异有统计学意义(P<0.05)。结论:用布地奈德福莫特罗粉吸入剂治疗肺结节病的疗效显著,可有效地缓解患者的临床症状。
Objective:To explore the efficacy of budesonide and formoterol powder inhalation in the treatment of pulmonary sarcoidosis.Methods:40 patients with pulmonary sarcoidosis were studied.They were divided into cyclophosphamide group(n=20)and budesonide formoterol group(n=20)by random table method.Patients in the cyclophosphamide group were treated with cyclophosphamide and patients in the budesonide and formoterol group were treated with budesonide and formoterol powder inhalation,and then the treatment effects of the two groups were compared.Results:After treatment,14 patients(70.00%)in budesonide and formoterol group showed significant clinical effect,3 patients(15.00%)showed improvement,and 3 patients(15.00%)showed no effect.In the cyclophosphamide group,there were 12 patients(60.00%)with significant clinical effect,3 patients(15.00%)with improvement,and 5 patients(25.00%)with no effect.The total effective rate in budesonide and formoterol group(85.00%(17/20))was higher than that in cyclophosphamide group(75.00%(15/20)),and the difference was statistically significant(P<0.05).Conclusion:Inhalation of budesonide formoterol powder is effective in the treatment of pulmonary sarcoidosis,and can effectively relieve the clinical symptoms of patients.
作者
唐秀兰
TANG Xiulan(Chongqing Jiulongpo District Second People’s Hospital,Chongqing 400052,China)
关键词
布地奈德福莫特罗粉吸入剂
环磷酰胺
肺结节病
Budesonide formoterol powder inhalation
Cyclophosphamide
Pulmonary sarcoidosis
